In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis

European Journal of Pharmaceutical Sciences

Volumn 65, Issue , 2014, Pages 147-155

  Mukkavilli, Rao ^a   Pinjari, Jakir ^a   Patel, Bhavesh ^a   Sengottuvelan, Shankar ^a   Mondal, Subodh ^a   Gadekar, Ajit ^a   Verma, Manas ^a   Patel, Jignesh ^a   Pothuri, Lavanya ^a   Chandrashekar, Gopu ^a   Koiram, Prabhakar ^a   Harisudhan, Tanukrishnan ^a   Moinuddin, Ansari ^a   Launay, Delphine ^b   Vachharajani, Nimish ^a   Ramanathan, Vikram ^a   Martin, Denis ^b  

^a Advinus Therapeutics Private Limited Bangalore   (India)

^b Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

Allometric scaling; Bioanalysis; Bioavailability; Cytochrome P450; Preclinical pharmacokinetics

Indexed keywords

ANTILEISHMANIAL AGENT; DNDI VL 2098; NITROIMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PLASMA PROTEIN; UNCLASSIFIED DRUG; ANTIPARASITIC AGENT;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSFORMATION; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RAT; RECOMMENDED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL BODY WATER; VISCERAL LEISHMANIASIS; ANIMAL; BIOAVAILABILITY; DRUG SCREENING; HALF LIFE TIME; LEISHMANIASIS, VISCERAL; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARASITIC AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CRICETINAE; DOGS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HEPATOCYTES; HUMANS; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICROSOMES, LIVER; RATS;

EID: 84907965506     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.09.006     Document Type: Article

References (16)

1. P.R. Chaturvedi Prediction of pharmacokinetic properties using experimental approaches during early drug discovery Curr. Opin. Chem. Biol. 5 2001 452 460
2. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095
3. M. Dogra Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver Br. J. Pharmacol. 162 2011 226 236
4. Flockhart, D.A., 2007. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. < http://medicine.iupui.edu/clinpharm/ddis/table.asp >.
5. Gupta, S. et al., 2013. Nitroimidazo-oxazole compound DNDi-VL-2098 as a candidate for oral treatment of Visceral Leishmaniasis. In: Proceeding of: 5th International symposium on Drug Development for Orphan-Neglected Diseases (CTDDR-2013), Abs. No. P-75, pp. 134.
6. Harisudhan, T. et al., 2011. Preclinical pharmacokinetics and prediction of human PK of DNDI-VL-2098, a potential oral treatment for visceral leishmaniasis. In: Poster presented at AAPS.
7. M. Mahmood Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development Adv. Drug Deliv. Rev. 59 2007 1177 1192
8. I. Mehmood, and J.D. Balian Interspecies scaling: predicting clearance of drugs in humans: three different approaches Xenobiotica 26 1996 887 895
9. P.L. Olliaro Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004 Lancet. Infect. Dis 5 2005 763 774
10. Rao, M. et al. 2011. In-vitro metabolism and disposition of DNDI-VL-2098, a potential treatment for visceral leishmaniasis. In: Poster Presented at AAPS.
11. G.A.S. Romero, and M. Boelaert Control of visceral leishmaniasis in Latin America - a systematic review PLoS Neglected Tropical Diseases 4 1 2010 e584 10.1371/journal.pntd.0000584
12. V. Sharma, and J.H. McNeill To scale or not to scale: the principles of dose extrapolation Br. J. Pharmacol. 157 2009 907 921
13. S. Sundar Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic center Clin. Infect. Dis. 31 4 2000 1104 1107
14. S. Sundar Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use Clin. Infect. Dis. 55 4 2012 543 550
15. J. Van Griensven Combination therapy for visceral leishmaniasis Lancet. Infect. Dis 10 2010 184 194
16. D.F. Veber Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623